์นด๋ณดํ๋ผํด
์นด๋ณดํ๋ผํด์ ์์ ์ข ์ํ์์ ๋๋ฆฌ ์ฌ์ฉ๋๋ 2์ธ๋ ๋ฐฑ๊ธ๊ณ ํญ์ข ์์ ์ ๋๋ค. ์ฃผ๋ก ๋ค์ํ ์์ข ๋ฐ ์ก์ข ์ ์น๋ฃ์ ์ฌ์ฉ๋๋ฉฐ, ํนํ ์ ๋จ ์์ ํ **๋ฐ๋ ค๊ฒฌ ๊ณจ์ก์ข **์ ๋ณด์กฐ ์๋ฒ์ผ๋ก ๊ฐ์ฅ ์ ์๋ ค์ ธ ์์ต๋๋ค. **์์์ ํน์ง ๋ฐ ์ฅ์ :** * **๊ณ ์์ด์์์ ์์ ์ฑ:** ๊ณ ์์ด์๊ฒ ์น๋ช ์ ์ธ ํ๋ถ์ข ์ ์ ๋ฐํ๋ 1์ธ๋ ์ฝ๋ฌผ์ธ ์์คํ๋ผํด๊ณผ ๋ฌ๋ฆฌ, ์นด๋ณดํ๋ผํด์ ๋น๊ต์ ์์ ํ์ฌ ๊ณ ์์ด ํ์์๊ฒ๋ ์ผ์์ ์ผ๋ก ์ฌ์ฉ๋ฉ๋๋ค. * **๋ ์ฑ ๊ฐ์:** ์นด๋ณดํ๋ผํด์ ์ผ๋ฐ์ ์ผ๋ก '๋ ์ํ' ๋ฐฑ๊ธ๊ณ ์ฝ๋ฌผ๋ก ๊ฐ์ฃผ๋ฉ๋๋ค. ์์คํ๋ผํด์ ๋นํด ์ ๋ ์ฑ ๋ฐ ๊ตฌํ ์ ๋ฐ ๊ฐ๋ฅ์ฑ์ด ํ์ ํ ๋ฎ์ ์น๋ฃ ์ ํ์ ๊ณต๊ฒฉ์ ์ธ ์ ๋งฅ ์์ก ์ด๋จ๊ฐ ํ์ํ์ง ์์ต๋๋ค. * **๋ค์ํ ํ์ฉ:** ์ ์ ์ ๋งฅ ํฌ์ฌ ์ธ์๋ ์ฒด๊ฐ ๋ด(ํ์), ๋๋งฅ ๋ด ๋ฐ ๋ณ๋ณ ๋ด(๋ง ์ฌ์ฝ์ด๋, ๊ณ ์์ด ๋น๊ฐ ํ๋ฉด ์์ข ) ์ ์ฉ์์๋ ๊ฐ๋ฅ์ฑ์ ๋ณด์ฌ์ฃผ์์ต๋๋ค.
์์ฉ ๊ธฐ์ : Carboplatin acts as a **bifunctional alkylating agent**. * **Cellular Entry & Activation:** Once inside the cell, the drug undergoes aquation (water molecules replace the cyclobutanedicarboxylate leaving group), forming highly reactive, positively charged platinum complexes. * **DNA Crosslinking:** These active complexes bind covalently to nucleophilic sites on DNA (primarily the N7 position of guanine and adenine). * **Inhibition:** This binding creates **intra-strand and inter-strand crosslinks** in the DNA double helix, physically obstructing DNA polymerases and RNA polymerases. * **Apoptosis:** The resulting DNA damage inhibits DNA replication, RNA transcription, and protein synthesis, ultimately triggering apoptosis (programmed cell death). > **Note:** Carboplatin is **cell-cycle nonspecific**, meaning it can damage cells during any phase of the cell cycle, though cells are most vulnerable during the G1 and S phases.
๋๋ฌผ ์ข ๋ณ ์ฉ๋
- Antineoplastic ยท 300-350 mg/m2 ยท IV ยท every 3 weeks ยท Dosage may need adjustment in patients with reduced renal function.
- Neoplastic diseases (All uses) ยท 300 mg/m2 ยท IV ยท q3-4wk ยท As determined by oncology protocol ยท Injected into the side port of a freely running i.v. infusion of 0.9% NaCl over a 10-15 min period.
- Neoplastic diseases (Intrapleural/intraperitoneal) ยท 225-300 mg/m2 ยท Intrapleural/Intraperitoneal ยท As directed by specialist ยท As determined by oncology protocol ยท Diluted in 0.9% NaCl or 5% dextrose water over a 5-10 min period. Consult a veterinary oncology specialist before administering via this route.
- Adenocarcinoma ยท Intralesional use may be considered ยท Intralesional
- Antineoplastic ยท 180-260 mg/m2 ยท IV ยท every 3 weeks ยท Has also been administered intratumorally for nasal planum carcinomas.
- Neoplastic diseases (All uses) ยท 200 mg/m2 ยท IV ยท q3-4wk ยท As determined by oncology protocol ยท Injected into the side port of a freely running i.v. infusion of 0.9% NaCl over a 10-15 min period. Monitor for delayed/unpredictable side effects.
- Neoplastic diseases (Intrapleural/intraperitoneal) ยท 200-240 mg/m2 ยท Intrapleural/Intraperitoneal ยท As directed by specialist ยท As determined by oncology protocol ยท Diluted in 0.9% NaCl or 5% dextrose water over a 5-10 min period. Consult a veterinary oncology specialist before administering via this route.
ํฌ์ฌ ๊ฒฝ๋ก
๊ธ๊ธฐ
- History of hypersensitivity to carboplatin or other platinum agents
- Severe bone marrow depression
- Pregnancy (fetotoxic and embryotoxic - Category D)
์ด์๋ฐ์
- Bone marrow suppression (neutropenia, thrombocytopenia)
- Anorexia
- Vomiting (typically 2-4 days post-dose)
- Hepatotoxicity (elevated bilirubin and liver enzymes)
- Nephrotoxicity (less frequent than cisplatin)
- Neuropathies (rare)
- Ototoxicity (rare)
- Anaphylactoid reactions (rare)
- Hyperuricemia
์ฝ๋ฌผ ์ํธ์์ฉ
- Aminoglycosides ยท Potential for increased risk of nephrotoxicity or ototoxicity. ยท major
- Cisplatin ยท Patients previously treated with cisplatin have an increased risk of developing neurotoxicity or ototoxicity after receiving carboplatin.
- Myelosuppressive drugs ยท The leukopenic or thrombocytopenic effects secondary to carboplatin may be enhanced.
- Radiation therapy ยท Potential for increased hematologic toxicity.
- Vaccines ยท Live or killed virus vaccines administered after therapy may have reduced efficacy. Carboplatin may also potentiate live virus vaccine replication and increase adverse effects.
- Nephrotoxic agents (e.g., NSAIDs, Amphotericin B) ยท Increased risk of cumulative nephrotoxicity. ยท major
- Vaccines (live) ยท May adversely affect the safety and efficacy of vaccinations due to immunosuppression. ยท major
- Radiotherapy ยท Potential to act as a radiosensitizer for patients receiving concomitant radiotherapy. ยท moderate
๋ชจ๋ํฐ๋ง
- CBC (Complete Blood Count) to monitor nadir
- Serum electrolytes
- Uric acid
- Baseline renal and hepatic function tests
๊ณผ์ฉ๋
An overdose of carboplatin is expected to cause severe, aggravated effects associated with the drug's primary toxicities: **bone marrow suppression, nephrotoxicity, and hepatotoxicity**. * **Monitoring:** Closely monitor for neurotoxicity, ototoxicity, hepatotoxicity, and nephrotoxicity. * **Treatment:** Therapy is primarily supportive as no specific antidote is available. Plasmapheresis or hemodialysis could potentially be of benefit in rapidly removing the drug from systemic circulation.
VetSheet ์ฝ๋ฌผ ๋ ํผ๋ฐ์ค๋ ๋ฉดํ ์์ ์ ๋ฌธ๊ฐ๋ฅผ ์ํ ์์ ์์ฌ๊ฒฐ์ ๋ณด์กฐ ๋๊ตฌ์ด๋ฉฐ, ์ ๋ฌธ์ ํ๋จ์ด๋ ์ ์กฐ์ฌ์ ์ต์ ๋ผ๋ฒจ์ ๋์ ํ์ง ์์ต๋๋ค.